Contact Dates

This section is intended to provide general information about reporting contact dates for infusions (transplant, cellular therapy, and gene therapy).

• Determining Contact Dates
• Subsequent Infusions and Contact Dates

Manual Updates
Sections of the Forms Instruction Manual are frequently updated. The most recent updates to the manual can be found below. For additional information, select the manual section and review the updated text.

If you need to review the historical Manual Change History for this form, reference the retired manual section on the Retired Forms Manuals.

Date	Manual Section	Add/Remove/Modify	Description
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	Example 5 updated to a new example. The prior example 5 is now example 7: Example 5: The recipient had a subsequent allo transplant for poor graft function. – The recipient has their first allo transplant on 3/1/2023 and a subsequent allo transplant from the same donor for the indication of poor graft function / insufficient donor chimerism on 4/15/2023. – Report the Day 100 contact date as the appropriate date for the reporting period since a new Pre-TED (2400) / Disease Classification (2402) is not required for allo boosts.
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	Example 6 updated to a new example. The prior example 6 is now example 8: Example 6: The recipient had a subsequent allo transplant for poor graft function and death occurred in the same reporting period. – The recipient had their first allo transplant on 3/1/2023 and a subsequent allo transplant form the same donor for poor graft function / insufficient donor chimerism recovery on 4/15/2023; however, the recipient passed away on 5/20/2023. – Report the Day 100 contact date as the death, 5/20/2023.
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	Example 10 updated: Example 10: The recipient had a subsequent Donor Lymphocyte Infusion (DLI) or subsequent allogeneic boost. The recipient has their first transplant on 1/21/22 and receives a DLI or allogeneic boost on 2/27/2022. Lymphodepleting therapy or preparative regimen may or may not be given and does not affect the contact date. Report the Day 100 contact date as a date appropriate to the reporting period. A DLI (2199) form should be completed for each DLI or allogeneic boost received in the reporting period. The Post-TED (2450) or Post-Infusion follow up (2100) form should not be completed early to report a DLI or allogeneic boost.
4/24/2026	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Modify	On Demand DCI Reporting blue box updated above example 10: On Demand DLI DCI Reporting: DLIs and allogeneic boosts can be reported prior to the Post-TED (2450) or Post-Infusion Follow Up (2100) Form due date by creating a Indication for CIBMTR Data Reporting (2814) Form on demand. When the Post-TED (2450) or Post-Infusion Follow Up (2100) form is completed at the due date, and no other infusions were given in the reporting period, report the DLI as a subsequent infusion, which will create a new Indication for CIBMTR Data Reporting (2814) Form. Submit a ticket via CIBMTR Center Support to request the form be made NRQ.
4/19/2025	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Add	Example 4 added: The recipient had a subsequent auto transplant for graft failure and death occurred in the same reporting period. The recipient has their first transplant on 3/1/2023 and a subsequent auto transplant for the indication of graft failure/insufficient hematopoietic recovery on 4/15/2023 and death occurred on 5/20/2023. Report the Day 100 contact date as the date of death, 5/20/2023.
4/19/2025	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Add	Subsequent Cell Therapy and Death blue box added: Subsequent Cell Therapy and Death: For a subsequent cellular therapy, if the Cellular Therapy Essential Data Pre-Infusion (4000) is requested via CIBMTR Center Support to be made “NRQ”, the death and subsequent infusion can be reported on the same form.
4/19/2025	Reporting Instructions Overview: Contact Dates – Subsequent Infusions and Contact Dates	Add	Example 9 added: The recipient had a subsequent non-genetically modified cellular therapy and death occurred in the same reporting period. The recipient has their first transplant on 1/21/23 and a non-genetically modified cellular therapy infusion on 2/15/23. Death occurred on 3/1/23. Report the Day 100 contact date as the date of death, 3/1/23
7/26/2024	Reporting Instructions Overview: Contact Dates	Add	Contact Dates Reporting Instruction Overview added.

Copyright © 2004-2026 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.